Investigation of the synergistic effect of glimepiride and rosuvastatin on alloxan-induced diabetic rat
- PDF / 716,419 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 14 Downloads / 191 Views
RESEARCH ARTICLE
Investigation of the synergistic effect of glimepiride and rosuvastatin on alloxan-induced diabetic rat Debashish Mondol 1 & Md. Nahinul Islam 1 & Sonchita Biswas 1 & Protic Jodder 1 & Samiron Sana 1 & Md. Abu Saleh 2 & Md. Rafiqul Islam 1 Received: 26 June 2020 / Accepted: 12 October 2020 # Springer Nature Switzerland AG 2020
Abstract Purpose Diabetes mellitus is characterized by having a multitude of life-threatening secondary complications, particularly dyslipidemia, which ultimately leads to the development of comorbid diseases, such as cardiovascular diseases. This research work was designed to investigate the synergistic effect of glimepiride (1 mg/kg b.w.) and rosuvastatin (10 mg /kg b.w.) on alloxan-induced diabetic rats having dyslipidemia. Methods Diabetes was induced by injecting alloxan (120 mg/kg b.w.) intraperitoneally. The experiment was conducted to determine the level of blood glucose, HbA1c, lipid profile, and body weight variation of rats. Results This study’s outcomes suggested that the combination therapy showed more statistically significant effect on blood glucose level, HbA1c level, lipid profile, and body weight variation than any single therapy. While the glimepiride monotherapy showed a statistically considerable effect on blood glucose level, HbA1c level, and body weight variation, the rosuvastatin treated group gave statistically non-significant effect on these parameters except body weight variation, which was found as downward trend. In addition, the rosuvastatin treated group showed a healthy lipid profile compared to glimepiride treated group. Conclusions Concluding the results of this study, it can be said that the treatment of glimepiride in combination with rosuvastatin may be more efficacious than monotherapy for preventing diabetes in rats with dyslipidemia. Keywords Diabetes . Dyslipidemia . Cardiovascular disease . Hyperglycemia . Alloxan . Combination therapy
Introduction Sulfonylureas, commonly used for the treatment of non-insulindependent diabetes mellitus (NIDDM), are categorized as insulin secretagogues, which stimulate endogenous insulin secretion by blocking K+-ATP channels after binding with sulphonylurea receptor 1 present on the β-cell plasma membrane [1, 2]. It has also been recognized that the contribution to sulfonylureas’ hypoglycemic action is mediated by their extra-pancreatic effects [3] such as promotion of glucose utilization in peripheral tissues or suppression of glucose output from the liver [4–6]. Glimepiride is a
* Md. Rafiqul Islam [email protected] 1
Department of Pharmacy, Faculty of Biological Science and Technology, Jashore University of Science and Technology, 7408 Jashore, Bangladesh
2
Department of Biochemistry and Molecular Biology, Jahangirnagar University, Savar, 1342 Dhaka, Bangladesh
second-generation sulfonylurea of which therapy shows reduced potential for hypoglycemia and may have supplementary actions contributing to glycemic control [7]. Diabetes is a multifactorial disorder associated with a remarkab
Data Loading...
